Boehringer Ingelheim Pharmaceuticals Inc. et al v. Aurobindo Pharma Ltd. et al.
| Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim International GmbH and Boehringer Ingelheim Corporation |
| Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. |
| 1:2021cv01485 |
| October 22, 2021 |
| US District Court for the District of Delaware |
| Colm F Connolly |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on December 1, 2021. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 10 STIPULATION TO EXTEND TIME to Answer, Move, or Otherwise Respond to the Complaint to January 18, 2022 - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc.. (Connolly, Arthur) |
SO ORDERED, re #10 STIPULATION TO EXTEND TIME to Answer, Move, or Otherwise Respond to the Complaint to January 18, 2022, filed by Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd. Reset Answer Deadlines: Aurobindo Pharma Ltd. answer due 1/18/2022; Aurobindo Pharma USA, Inc. answer due 1/18/2022. Ordered by Judge Colm F. Connolly on 12/1/2021. (kmd)
|
| Filing 9 SUMMONS Returned Executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH. Aurobindo Pharma USA, Inc. served on 11/9/2021, answer due 11/30/2021. (Dellinger, Megan) |
| Filing 8 SUMMONS Returned Executed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH. Aurobindo Pharma Ltd. served on 11/9/2021, answer due 11/30/2021. (Dellinger, Megan) |
| Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:21-cv-01485-CFC, 1:21-cv-01486-CFC, 1:21-cv-01487-CFC (rjb) |
| Filing 7 Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma Ltd. on 10/22/2021. (twk) |
| Filing 6 Summons Issued with Magistrate Consent Notice attached as to Aurobindo Pharma USA, Inc. on 10/22/2021. (twk) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc.. (twk) |
| Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,090,323 B2. (twk) |
| Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: Not earlier than October 8, 2021. Date of Expiration of Patent: April 3, 2034. (twk) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) |
| Filing 1 COMPLAINT filed against Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3727443.) - filed by Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH. (Attachments: #1 Exhibit A, #2 Civil Cover Sheet)(twk) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
